CTLA4 and colorectal carcinoma: The results revealed that the total IPS and IPS for CTLA-4 blocker in the low-risk group were significantly higher than that in the high-risk group (Fig. 6C), which strongly predicted that CRC patients with lower risk scores would have better immunotherapy response, especially for CTLA-4 blocker.